Arabic Arabic English English French French German German

Icosavax: Giving VLPs the VIP Treatment

Icosavax’s virus-like particle (VLP) technology, developed at UW’s Institute for Protein Design (IPD), is designed to address a challenge that has impeded wider use of VLP vaccines: How to construct and manufacture VLPs capable of displaying complex viral antigens that have been difficult to successfully produce at scale, including for RSV and hMPV . . .

Get GEN Edge Today!

The post Icosavax: Giving VLPs the VIP Treatment appeared first on GEN – Genetic Engineering and Biotechnology News.

Read More

Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post

Benefits of continuing to provide life-saving HIV services outweigh the risk of COVID-19 transmission by 100 to 1

Next Post

GW Pharmaceuticals and U.S. Subsidiary Greenwich Biosciences to Present Data at the 2021 American Academy of Neurology (AAN) Annual Meeting

Related Posts